ArticleThe Laryngoscope2026
Immunosuppression and Surgery-Free Interval in Granulomatosis With Polyangiitis Airway Stenosis.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Speech and language therapy management of laryngotracheal stenosis - what has changed.Current opinion in otolaryngology & head and neck surgery · 2026Review
- Immunosuppression and Surgery-Free Interval in Granulomatosis With Polyangiitis Airway Stenosis.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSubglottic and tracheal stenosis (SGS, TS) are severe manifestations of granulomatosis with polyangiitis (GPA), often-requiring endoscopic airway intervention and systemic immunosuppression. Rituximab (RTX) has shown efficacy for systemic GPA, but its role in SGS and TS remains unclear, with reports of both benefit and relapse. This study evaluated the impact of RTX and cyclophosphamide (CTX) on surgery-free intervals (SFIs) in GPA-associated SGS and TS.
methodsA retrospective chart review was conducted on GPA patients with SGS or TS treated at a tertiary center between 1992 and 2023. Therapeutic RTX exposure was defined as 3-9 months post-induction or within 1 year of maintenance, and CTX during regular dosing before transitioning to another maintenance regimen. SFIs, calculated as time between endoscopic interventions, were compared with and without RTX and CTX exposure using weighted t-tests.
resultsA total of 55 patients met inclusion; 44 (80%) underwent at least one endoscopic intervention and 34 of those patients (77%) received RTX and/or CTX. Median follow-up time was 10.2 years (range 0.8-29.5 years). Mean SFIs were significantly longer during therapeutic RTX exposure or remission (45 ± 8 months) versus non-therapeutic intervals (20 ± 6 months) (p = 0.046). Prior RTX or CTX use, though not definitionally therapeutic, significantly increased mean SFI from 22 to 25 months compared to no exposure (p = 0.029). CTX alone did not significantly increase SFI.
conclusionRituximab may contribute to longer intervals between endoscopic airway intervention and delay relapse in GPA-related airway stenosis, supporting its role in stabilization of airway manifestations. Multidisciplinary management remains essential for this life-threatening GPA manifestation. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.